JP2018504141A5 - - Google Patents

Download PDF

Info

Publication number
JP2018504141A5
JP2018504141A5 JP2017556782A JP2017556782A JP2018504141A5 JP 2018504141 A5 JP2018504141 A5 JP 2018504141A5 JP 2017556782 A JP2017556782 A JP 2017556782A JP 2017556782 A JP2017556782 A JP 2017556782A JP 2018504141 A5 JP2018504141 A5 JP 2018504141A5
Authority
JP
Japan
Prior art keywords
government
awarded
health
certain rights
national institutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017556782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504141A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/013765 external-priority patent/WO2016118433A1/en
Publication of JP2018504141A publication Critical patent/JP2018504141A/ja
Publication of JP2018504141A5 publication Critical patent/JP2018504141A5/ja
Pending legal-status Critical Current

Links

JP2017556782A 2015-01-20 2016-01-17 非標的化アデノウイルス変異体および関連する方法 Pending JP2018504141A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105284P 2015-01-20 2015-01-20
US62/105,284 2015-01-20
PCT/US2016/013765 WO2016118433A1 (en) 2015-01-20 2016-01-17 Detargeted adenovirus variants and related methods

Publications (2)

Publication Number Publication Date
JP2018504141A JP2018504141A (ja) 2018-02-15
JP2018504141A5 true JP2018504141A5 (enExample) 2019-02-07

Family

ID=56417617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017556782A Pending JP2018504141A (ja) 2015-01-20 2016-01-17 非標的化アデノウイルス変異体および関連する方法

Country Status (4)

Country Link
US (3) US10376549B2 (enExample)
EP (1) EP3247807B1 (enExample)
JP (1) JP2018504141A (enExample)
WO (1) WO2016118433A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
CN117384961A (zh) 2016-02-23 2024-01-12 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN117534735A (zh) * 2016-03-31 2024-02-09 欧洲分子生物学实验室 腺病毒外壳蛋白衍生递送载体
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
GB201802539D0 (en) * 2018-02-16 2018-04-04 Univ College Cardiff Consultants Ltd Modified adenoviruses
MX2020010499A (es) 2018-04-09 2020-10-28 Salk Inst For Biological Studi Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.
EP3812465A1 (en) * 2019-10-21 2021-04-28 Universität Ulm Adenovirus comprising a modified adenovirus hexon protein

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) 1968-10-17 1970-08-24
AU1449792A (en) * 1991-02-14 1992-09-15 La Jolla Cancer Research Foundation A novel integrin specificity for the hiv tat protein
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
EP1112372A1 (en) * 1998-09-11 2001-07-04 Genvec, Inc. Alternatively targeted adenovirus
US20060057553A1 (en) * 2000-05-30 2006-03-16 Estuardo Aguilar-Cordova Chimeric viral vectors for gene therapy
WO2002081497A2 (en) * 2001-04-04 2002-10-17 University Of Rochester αξβ3 INTEGRIN-BINDING POLYPEPTIDE MONOBODIES AND THEIR USE
US9175309B2 (en) * 2001-09-29 2015-11-03 Industry-University Cooperation Foundation Hanyang University Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus
US20040002060A1 (en) * 2002-01-24 2004-01-01 Novartis Ag Fiber shaft modifications for efficient targeting
JP4328116B2 (ja) * 2003-03-25 2009-09-09 国立医薬品食品衛生研究所長 変異型アデノウイルスベクター
US20060281090A1 (en) * 2003-05-01 2006-12-14 University Of Washington Uw Tech Transfer- Invention Licensing Capsid-modified adenovirus vectors and methods of using the same
WO2007094653A1 (en) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
CN102014948A (zh) * 2008-02-07 2011-04-13 安德鲁·贝克 腺病毒向性的调节
EP2498791B1 (en) * 2009-11-09 2014-12-24 GenVec, Inc. Methods of propagating monkey adenoviral vectors

Similar Documents

Publication Publication Date Title
JP2018504141A5 (enExample)
JP2021502979A5 (enExample)
JP2021503478A5 (enExample)
WO2018081648A3 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
JP2021500894A5 (enExample)
EP3762031A4 (en) ANTI-CLAUDINE ANTIBODIES 18.2 AND THEIR USES
JP2018012698A5 (enExample)
JP2020010717A5 (enExample)
JP2018100276A5 (enExample)
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
JP2016196495A5 (enExample)
JP2018533683A5 (enExample)
HUE054103T2 (hu) Izokinolin-3-il-karboxamidok, ezek elõállítása és alkalmazása
WO2016077381A8 (en) Anti-interleukin-33 antibodies and uses thereof
WO2015179658A3 (en) Anti-gpc3 antibodies and immunoconjugates
JP2016028081A5 (enExample)
JP2019536002A5 (enExample)
WO2015153513A8 (en) Anti-ox40 antibodies and methods of use
HUE062189T2 (hu) Aktivin-ACTRII-antagonisták és alkalmazások mielodiszpláziás szindróma kezelésére
TR201810635T4 (tr) Anti-jagged1 antikorları ve kullanım yöntemleri.
TWD173737S (zh) 肌肉鍛鍊機器
JP2017537928A5 (enExample)
EP3415518A4 (en) MACROCYCLUS AND COMPOSITION THEREOF
JP2015186128A5 (enExample)
PL3493812T3 (pl) Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej